Literature DB >> 20514533

Mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease: a report of two cases.

Joo Han Lim1, Moon Hee Lee, Hyeon Gyu Yi, Chul Soo Kim, Jun Hyung Kim, Sun U Song.   

Abstract

Severe graft-versus-host disease (GVHD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT). However, there have been only a few limited therapeutic options for the treatment of GVHD. Here we have reported two cases of the patients with acute steroid-refractory GVHD who underwent allogeneic HSCT. These patients received infusions of third-party clonal mesenchymal stem cells (cMSCs), which were isolated by a subfractionation culturing method (SCM) developed recently by our group, and showed marked improvement of the disease. MSCs represent a new potential therapeutic option in the treatment of steroid-refractory acute GVHD. They showed safety and improved clinical findings of the acute GVHD patients. However, further investigations are needed to understand the accurate mechanisms of MSCs and larger well-designed human clinical trials are necessary to prove further the safety and efficacy of the cMSCs for the treatment of acute GVHD patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20514533     DOI: 10.1007/s12185-010-0606-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  10 in total

1.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Authors:  Katarina Le Blanc; Ida Rasmusson; Berit Sundberg; Cecilia Götherström; Moustapha Hassan; Mehmet Uzunel; Olle Ringdén
Journal:  Lancet       Date:  2004-05-01       Impact factor: 79.321

2.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

3.  Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia.

Authors:  L Ball; R Bredius; A Lankester; J Schweizer; M van den Heuvel-Eibrink; H Escher; W Fibbe; M Egeler
Journal:  Leukemia       Date:  2007-11-01       Impact factor: 11.528

4.  Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues.

Authors:  A J Friedenstein; K V Petrakova; A I Kurolesova; G P Frolova
Journal:  Transplantation       Date:  1968-03       Impact factor: 4.939

5.  The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells.

Authors:  A J Friedenstein; R K Chailakhjan; K S Lalykina
Journal:  Cell Tissue Kinet       Date:  1970-10

6.  Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.

Authors:  Hillard M Lazarus; Omer N Koc; Steven M Devine; Peter Curtin; Richard T Maziarz; H Kent Holland; Elizabeth J Shpall; Philip McCarthy; Kerry Atkinson; Brenda W Cooper; Stanton L Gerson; Mary J Laughlin; Fausto R Loberiza; Annemarie B Moseley; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2005-05       Impact factor: 5.742

Review 7.  Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management.

Authors:  Daniel Couriel; Humberto Caldera; Richard Champlin; Krishna Komanduri
Journal:  Cancer       Date:  2004-11-01       Impact factor: 6.860

Review 8.  Management of acute graft-versus-host disease.

Authors:  Andrea Bacigalupo
Journal:  Br J Haematol       Date:  2007-04       Impact factor: 6.998

9.  Variations of clonal marrow stem cell lines established from human bone marrow in surface epitopes, differentiation potential, gene expression, and cytokine secretion.

Authors:  S U Song; C S Kim; S P Yoon; S K Kim; M H Lee; J S Kang; G S Choi; S H Moon; M S Choi; Y K Cho; B K Son
Journal:  Stem Cells Dev       Date:  2008-06       Impact factor: 3.272

10.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.

Authors:  Katarina Le Blanc; Francesco Frassoni; Lynne Ball; Franco Locatelli; Helene Roelofs; Ian Lewis; Edoardo Lanino; Berit Sundberg; Maria Ester Bernardo; Mats Remberger; Giorgio Dini; R Maarten Egeler; Andrea Bacigalupo; Willem Fibbe; Olle Ringdén
Journal:  Lancet       Date:  2008-05-10       Impact factor: 79.321

  10 in total
  10 in total

1.  Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC).

Authors:  Igor B Resnick; Claudine Barkats; Michael Y Shapira; Polina Stepensky; Allan I Bloom; Avichai Shimoni; David Mankuta; Nira Varda-Bloom; Lyudmila Rheingold; Moshe Yeshurun; Bella Bielorai; Amos Toren; Tsila Zuckerman; Arnon Nagler; Reuven Or
Journal:  Am J Blood Res       Date:  2013-08-19

Review 2.  Role of mesenchymal stem cells in leukaemia: Dr. Jekyll or Mr. Hyde?

Authors:  Rebecca S Y Wong; Soon-Keng Cheong
Journal:  Clin Exp Med       Date:  2013-06-23       Impact factor: 3.984

3.  Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study.

Authors:  Kazuo Muroi; Koichi Miyamura; Kazuteru Ohashi; Makoto Murata; Tetsuya Eto; Naoki Kobayashi; Shuichi Taniguchi; Masahiro Imamura; Kiyoshi Ando; Shunichi Kato; Takehiko Mori; Takanori Teshima; Masaki Mori; Keiya Ozawa
Journal:  Int J Hematol       Date:  2013-07-17       Impact factor: 2.490

Review 4.  Insurance approval of mesenchymal stem cell for acute GVHD in Japan: need of follow up for some remaining concerns.

Authors:  Koichi Miyamura
Journal:  Int J Hematol       Date:  2016-01-12       Impact factor: 2.490

5.  Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells.

Authors:  Shyam A Patel; Pranela Rameshwar
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-09-01

6.  Mesenchymal stem cells as a novel vaccine platform.

Authors:  Suzanne L Tomchuck; Elizabeth B Norton; Robert F Garry; Bruce A Bunnell; Cindy A Morris; Lucy C Freytag; John D Clements
Journal:  Front Cell Infect Microbiol       Date:  2012-11-16       Impact factor: 5.293

7.  Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases.

Authors:  Caroline M Wernicke; Thomas Gp Grunewald; Juenger Hendrik; Selim Kuci; Zyrafete Kuci; Ulrike Koehl; Ingo Mueller; Michaela Doering; Christina Peters; Anita Lawitschka; Hans-Jochem Kolb; Peter Bader; Stefan Burdach; Irene von Luettichau
Journal:  Int Arch Med       Date:  2011-08-15

8.  Double allogenic mesenchymal stem cells transplantations could not enhance therapeutic effect compared with single transplantation in systemic lupus erythematosus.

Authors:  Dandan Wang; Kentaro Akiyama; Huayong Zhang; Takayoshi Yamaza; Xia Li; Xuebing Feng; Hong Wang; Bingzhu Hua; Bujun Liu; Huji Xu; Wanjun Chen; Songtao Shi; Lingyun Sun
Journal:  Clin Dev Immunol       Date:  2012-07-09

9.  Toll-like receptor 3 and suppressor of cytokine signaling proteins regulate CXCR4 and CXCR7 expression in bone marrow-derived human multipotent stromal cells.

Authors:  Suzanne L Tomchuck; Sarah L Henkle; Seth B Coffelt; Aline M Betancourt
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

10.  Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study.

Authors:  Hyeon Gyu Yi; Seung-Ah Yahng; Inho Kim; Je-Hwan Lee; Chang-Ki Min; Jun Hyung Kim; Chul Soo Kim; Sun U Song
Journal:  Korean J Physiol Pharmacol       Date:  2015-12-31       Impact factor: 2.016

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.